Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial

被引：0
|
作者：
Shen, Yuanming
Kong, Beihua
Xia, Bairong
Wang, Fei
Yin, Rutie
Li, Qingshui
Yue, Ying
Kang, Shan
He, Liping
Wang, Ke
Meng, Yuanguang
Wang, Shixuan
Qu, Pengpeng
Huang, Xianghua
Guo, Ruixia
Yan, Ping
Pan, Mei
Lou, Ge
Cheng, Wenjun
Xie, Xing
机构：
[1] Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[3] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China
[4] Shandong Prov Hosp, Jinan, Peoples R China
[5] Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China
[6] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[7] Jilin Univ, Affiliated Hosp 1, Changchun, Peoples R China
[8] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[9] Hebei Tumor Hosp, Shijiazhuang, Hebei, Peoples R China
[10] Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Guizhou, Peoples R China
[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[12] Chinese Peoples Liberat Army Gen Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China
[13] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[14] Tianjin Cent Hosp Gynecol & Obstet, Tianjin, Peoples R China
[15] Hebei Med Univ, Hosp 2, Shijiazhuang, Hebei, Peoples R China
[16] Zhengzhou Univ, Affiliated Hosital 1, Zhengzhou, Peoples R China
[17] Hebei Gen Hosp, Shijiazhuang, Hebei, Peoples R China
[18] Maternal & Child Hlth Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China
[19] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[20] Jiangsu Prov Hosp, Nanjing, Peoples R China
[21] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5556
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Sorio, R.
    Breda, E.
    Ferrandina, G.
    Gebbia, V.
    Musso, P.
    Gallo, C.
    Perrone, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.
    Mahner, S.
    Meier, W.
    Du Bois, A.
    Brown, C.
    Lorusso, D.
    Ferrero, A.
    Cretin, J.
    Havsteen, H.
    Bessette, P.
    Angleitner-Boubenizek, L.
    Vergote, I. B.
    Vasey, P. A.
    Gebski, V.
    Slama, B.
    Herrstedt, J.
    Kaizer, L.
    Georgoulopoulos, A.
    Reed, N.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Prospective, randomised phase II trial: carboplatin and oral etoposide versus carboplatin and cyclophosphamide in the first-line treatment of ovarian cancer
    Sehouli, J
    Horstkamp, B
    Schonborn, I
    Kettner, H
    Lichtenegger, W
    Noggo
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 1259 - 1263
  • [34] Combination paclitaxel plus Carboplatin versus paclitaxel with alternating Carboplatin and cisplatin as first line treatment for advanced ovarian cancer (AOC)
    Aravantinos, G
    Fountzilas, G
    Kosmides, P
    Stathopoulos, GP
    Pavlidis, N
    Dimopoulos, MA
    Bafaloukos, D
    Papakostas, P
    Papadimitriou, C
    Nikolaides, G
    Skarlos, DV
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
  • [35] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
  • [37] Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
    Zhou, T.
    Yang, Y.
    Ma, S.
    Lin, L.
    Zhou, T.
    Zhang, C.
    Ding, X.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    Huang, Y.
    Zhang, L.
    ESMO OPEN, 2021, 6 (06)
  • [38] Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer
    Ozols, RF
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 : 9 - 12
  • [39] Randomized, open-label, phase III, multicenter trial comparing AT (doxorubicin, paclitaxel) versus FAC (5-fluorouracil, doxorubicin, cyclophosphamide) as first-line treatment for patients with metastatic breast cancer
    Tjulandin, SA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 10 - 10
  • [40] A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
    Jin, M.
    Liu, H.
    Lin, Z.
    Xue, J.
    Liu, J.
    Bao, L.
    Luo, Z.
    Yu, X.
    Li, S.
    Hu, J.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S311 - S311
12345